Boulding Mark Elliott

Exec. VP And CLO | Exec. VP And CLO

1 company

Good

Trades Analyzed

12M Win Rate

30.0%

Avg 3M Return

+0.4%

Avg 12M Return

-12.5%

Boulding Mark Elliott is an Exec. VP And CLO at PTC Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 46 sells.

Estimated insider holdings value: $8.5M based on current market prices.

Holdings by Company

PTCTApr 6, 2026

Current Shares107.5K

Value$8.49M

Net Activity-635,367

Bought: 0Sold: 635.4K

Showing 10 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Apr 6, 2026	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,265	$69.45	$157,293.27	-1.1%	-	-
Jan 9, 2026	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	6,347	$77.06	$489,080.53	-0.9%	-8.6%	-
Jan 7, 2026	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	6,618	$77.31	$511,641.42	-0.7%	-9.9%	-
Jan 5, 2026	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,266	$75.55	$171,191.98	-0.6%	-10.2%	-
Nov 17, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,812	$75.99	$213,686.89	-0.9%	-8.5%	-
Oct 7, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	3,375	$63.43	$214,091.17	-1.1%	+20.1%	-
Oct 6, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	24,921	$65.75	$1,638,548.63	-2.1%	+18.5%	-
Sep 12, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	47,249	$61.18	$2,890,586.51	-6.1%	+23.5%	-
Aug 15, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,813	$48.58	$136,655.54	-2.6%	+53.5%	-
May 16, 2025	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,812	$46.13	$129,716.88	-1.3%	+5.8%	+55.3%